Safety was analyzed in the total vaccinated cohort,
which included all participants who received
at least one dose of HZ/su or placebo. Efficacy
was analyzed in the total vaccinated cohort
and in the modified vaccinated cohort (primary
analysis); in the latter cohort, participants who
8.1 (Cytel).